

1 **Circulating serum miRNAs predict response to platinum chemotherapy in high-grade serous**
2 **ovarian cancer**

3

4 Kazuhiro Suzuki¹, Akira Yokoi^{1,2}, Juntaro Matsuzaki³, Kosuke Yoshida^{1,2}, Yusuke Yamamoto⁴,
5 Tomoyasu Kato⁵, Mitsuya Ishikawa⁵, Takahiro Ochiya⁶, Hiroaki Kajiyama¹

6

7 ¹ Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65
8 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

9 ² Institute for Advanced Research, Nagoya University, Furo-cho, Chikusa-ku, 464-8601 Nagoya
10 464-8601, Japan

11 ³ Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen,
12 Minato-ku, Tokyo 105-8512, Japan

13 ⁴ Laboratory of Integrative Oncology, National Cancer Center Research Institute, 5-1-1 Tsukiji,
14 Chuo-ku, Tokyo, 104-0045, Japan

15 ⁵ Department of Gynecology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo,
16 104-0045, Japan

17 ⁶ Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical
18 University, 6-1-1 Nishishinjuku, Shinjyuku-ku Tokyo 160-8402, Japan

19

20 **Corresponding author**

21 Akira Yokoi, M. D., Ph. D.

22 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine,
23 Tsuruma-cho 65, Showa-ku, Nagoya 466-8550, Japan

24 Tel: +81-52-744-2261

25 Fax: +81-52-744-2268

26 E-mail: ayokoi@med.nagoya-u.ac.jp

27

28 **Abstract**

29 **Background:** Platinum chemotherapy is the cornerstone of treatment for high-grade serous ovarian
30 cancer (HGSOC); however, validated biomarkers that can accurately predict platinum response are
31 lacking. Based on their roles in the underlying pathophysiology, circulating microRNAs are potential,
32 noninvasive biomarkers in cancer. In the present study, we aimed to evaluate the circulating miRNA
33 profiles of patients with HGSOC and to assess their potential utility as biomarkers to predict
34 platinum response.

35 **Methods:** Pretreatment serum samples collected from patients who received platinum chemotherapy
36 for stage III–IV HGSOC between 2008 and 2016 were analyzed using miRNA microarray. LASSO
37 logistic regression analysis was used to construct predictive models for treatment-free interval of
38 platinum (TFIp).

39 **Results:** The median follow-up was 54.6 (range, 3.5–144.1) months. The comprehensive analysis of
40 2,588 miRNAs was performed in serum samples of 153 eligible patients, and predictive models were
41 constructed using a combination of circulating miRNAs with an area under the receiver operating
42 characteristic curve of 0.944 for TFIp > 1 month, 0.637 for TFIp ≥ 6 months, 0.705 for TFIp ≥ 12
43 months, and 0.938 for TFIp ≥ 36 months. Each predictive model provided a significant TFIp
44 classification ($p = 0.001$ in TFIp >1 month, $p = 0.013$ in TFIp ≥ 6 months, $p < 0.001$ in TFIp ≥ 12
45 months, and $p < 0.001$ in TFIp ≥ 36 months).

46 **Conclusion:** Circulating miRNA profiles has potential utility in predicting platinum response in
47 patients with HGSOC and can aid clinicians in choosing appropriate treatment strategies.

48 **Keywords:**

49 high-grade serous ovarian cancer, platinum response, miRNA, biomarker

50

51 **Introduction**

52 According to the GLOBOCAN estimates, 313,959 new ovarian cancer cases and 207,252 ovarian
53 cancer-related deaths occurred worldwide in 2020 [1]. High-grade serous ovarian cancer (HGSOC),
54 the main epithelial ovarian cancer subtype [2], is already in advanced stage at diagnosis in most
55 cases; therefore, the 5-year survival rate of advanced-stage HGSOC is approximately 30% [3]. The
56 standard treatment strategy for HGSOC is primary debulking surgery followed by chemotherapy or
57 neoadjuvant chemotherapy with subsequent interval debulking surgery [4]. The introduction of
58 bevacizumab and Poly(ADP-ribose) polymerase inhibitors (PARPi) has expanded the spectrum of
59 available treatment alternatives, but consistent therapy efficacy is limited [5, 6]. Platinum
60 chemotherapy remains the most vital therapeutic agent for the treatment of both primary and
61 recurrent HGSOC [4].

62 Treatment-free interval of platinum (TFIp) is a commonly used decision criterion for
63 platinum rechallenge [7]. Similarly, the TFIp status has been used to classify patients in clinical trials
64 on ovarian cancer [8], [9]. However, the efficacy of platinum rechallenge was clearly demonstrated
65 in several phase II trials, which showed that platinum chemotherapy was no longer effective patients
66 with a TFIp of <6 months [10, 11], indicating that a TFIp of <6 months was not a consistent predictor
67 of response to platinum chemotherapy. There are various chemotherapy options for ovarian cancer,
68 such as platinum chemotherapy with or without the addition of bevacizumab or maintenance therapy
69 with or without the addition of bevacizumab and PARPi. For an expected short duration of TFIp with
70 platinum chemotherapy alone, the addition of bevacizumab or enhanced maintenance therapy should
71 be selected with the expectation of additional therapeutic benefit. In contrast, for an expected long
72 duration of TFIp with platinum chemotherapy alone, the patient may choose not to receive any
73 additional therapy or maintenance therapy. Therefore, accurate prediction of TFIp is essential for
74 treatment selection. Currently, validated biomarkers that predict response to platinum chemotherapy
75 in clinical settings are lacking.

76 MicroRNAs (miRNAs) are endogenous, small, noncoding, single-stranded RNAs that
77 regulate target gene expression and play vital roles in cancer progression [12, 13]. Importantly,
78 miRNAs are released from cells to stably exist in body fluids by escaping RNase degradation.
79 Circulating miRNAs in body fluids are wrapped up by extracellular vesicles, thereby intervening in
80 cell-to-cell communication in both the original and the distant microenvironments [14-16]. We have
81 previously demonstrated the potential role of circulating miRNAs as noninvasive diagnostic
82 biomarkers for ovarian cancer, with high accuracy and prognostic ability found in high-grade serous
83 carcinoma and ovarian clear cell carcinoma [17-19]. Recent studies have also reported the utility of
84 miRNA expression profiles in predicting therapeutic response in cancer [20, 21].

85 In the present study, we aimed to determine the utility of circulating miRNA profiles as
86 noninvasive biomarkers to predict platinum response in HGSOc. Thus, we investigated the
87 association between platinum response and circulating miRNA profiles before platinum therapy by
88 analyzing patients who did not receive bevacizumab or PARPi as first-line therapy to specifically
89 determine platinum response. Therefore, the present study provides novel evidence on the utility of
90 circulating miRNA profiles as noninvasive biomarkers to predict platinum response in HGSOc.

91 **Materials and methods**

92 **Patient selection**

93 This is a retrospective cohort study based on miRNA profiles identified in a previous study and on
94 the clinical information of the patients. In a previous study, we collected 4,046 serum samples from
95 patients with ovarian tumors and healthy controls admitted or referred to the National Cancer Center
96 Hospital between 2008 and 2016 [17]. Data are available from the NCBI database under the
97 accession number GSE106817. The present study included the pretreatment serum samples of 442
98 patients with ovarian tumors. The clinical information of patients, such as age, histologic subtype,
99 International Federation of Gynecology and Obstetrics stage, residual tumor volume, administration
100 of neoadjuvant or adjuvant chemotherapy, recurrence, and death, was retrospectively reviewed by

101 accessing the database of the Department of Gynecology of the National Cancer Center Hospital
102 (Tokyo, Japan). Patients with stage III–IV HGSOc were included after the exclusion of patients who
103 underwent surgery or chemotherapy before serum collection and those with a history of other cancers.
104 Follow-up was performed at least every 3 months for 2 years after the last platinum treatment. At the
105 time of follow-up, computed tomography was performed after at least every 6 months. Tumors were
106 evaluated using contrast-enhanced computed tomography every two cycles. The response to
107 chemotherapy was evaluated according to the Response Evaluation Criteria in Solid Tumors 1.1.

108 The present study was approved by the National Cancer Center Hospital Institutional
109 Review Board (approval no. 2015-376, 2016-29), and all participants provided written informed
110 consent.

111 **miRNA expression analysis**

112 The serum samples stored in the National Cancer Center Biobank were used for comprehensive
113 miRNA expression analysis using the 3D-Gene miRNA labeling kit and the 3D-Gene Human
114 miRNA Oligo Chip (Toray Industries Inc., Tokyo, Japan), which was designed to detect 2,588
115 miRNA sequences registered in miRBase (release 21) [22]. To that end, total RNA was extracted
116 from 300 μ L of the serum samples using the 3D-Gene RNA extraction reagent (Toray Industries Inc.,
117 Tokyo, Japan). In the present study focusing on circulating miRNAs released by ovarian cancer cells,
118 miRNAs were selected according to the criteria described in our previous study [17]. Among a total
119 of 2,038 miRNAs, 858 miRNAs were detected in extracellular vesicles derived from at least one
120 ovarian cancer cell line. Among these, 210 miRNAs that were identified based on a human serum
121 dataset were included in the final analysis [17].

122 **Statistical analysis**

123 In the present study, TFIp was defined as the time interval from the last platinum treatment
124 to the time of initial tumor progression or last contact and overall survival was defined as the time
125 interval from initial treatment to the time of death from any cause (Supplementary Figure 1).

126 Sensitivity, specificity, and accuracy of the circulating miRNAs in predicting TFIp were determined
127 using receiver operating characteristic (ROC) curve analysis and the area under the ROC curve
128 (AUC) was calculated. The ROC analysis was used to determine the TFIp with the best power, which
129 was used to develop a predictive model for platinum response. Thus, predictive index-positive cases
130 were considered as patients with a TFIp >X months. The sensitivity showed the predictive rate of
131 TFIp longer than X months, and the specificity showed the predictive rate of TFIp less than X
132 months. To calculate sensitivity, specificity, and accuracy, optimal cutoff values were set based on
133 the maximum point of the sum of sensitivity and specificity, i.e., Youden index. The 95% confidence
134 interval (95% CI) of the AUC was calculated and plotted in the ROC curve. Two-group comparison
135 was performed using Welch's *t*-test. LASSO logistic regression analysis was performed using the R
136 software (version 4.3.0; R Foundation for Statistical Computing, <http://www.R-project.org>),
137 *compute.es* (version 0.2-4), *glmnet* (version 2.0-3), *hash* (version 2.2.6), *MASS* (version 7.3-45),
138 *mutoss* (version 0.1-10), and *pROC* (version 1.8). ROC curves were compared using the DeLong test.
139 Pearson's χ^2 , Welch's *t* tests, and one-way analysis of variance were performed using SPSS Statistics
140 (version 29; IBM Corp., Armonk, NY, USA). Kaplan–Meier curves were used for the analysis of
141 TFIp and were compared using the generalized Wilcoxon test. A two-sided *p* value <0.05 were
142 considered statistically significant for all analyses.

143 **Results**

144 A total of 422 serum samples of patients with ovarian tumors were analyzed using the miRNA
145 microarray to obtain the comprehensive miRNA expression profiles of patients. After the exclusion
146 of serum samples from 262 patients with other ovarian cancer subtypes, 14 patients with stage I–II
147 cancer, 11 patients with insufficient clinical information, and 2 patients with low-quality microarray
148 results, the profiles of 153 patients were included in the final analysis (Figure 1).

149 The patient characteristics are summarized in Table 1. Briefly, all patients received
150 cytoreductive surgery and adjuvant chemotherapy, which typically included carboplatin plus

151 paclitaxel, without bevacizumab or PARPi. The median follow-up period was 54.6 (range,
152 3.5–144.1) months. The groups were created according to the initial TFIp, and 143, 122, 84, and 30
153 patients had TFIp > 1, ≥ 6, ≥ 12, and ≥ 36 months, respectively.

154 **Selection of circulating miRNA candidates, and construction of predictive models**

155 A total of 210 miRNAs selected as candidate biomarkers according to the method described in our
156 previous report were used in combination with other prognostic factors included in Table 1 [17]. In
157 each group, a predictive model was constructed using the LASSO logistic regression analysis. The
158 results are summarized in Table 1, and the details of the predictive model are shown in
159 Supplementary Table 1. Only one model was selected to predict TFIp in each group based on
160 DeLong test. The most appropriate predictive model was expressed as follows: model TFIp > 1
161 month: $\exp Y / (1 + \exp Y) | Y = (-0.43074 \times \text{miR-1228-5p}) + (-0.2713 \times \text{miR-1273g-3p}) + (0.2881$
162 $\times \text{miR-3917}) + (-0.15449 \times \text{miR-3940-5p}) + (0.03679 \times \text{miR-4708-3p}) + (-1.00381 \times \text{miR-4739}) +$
163 $(-0.0285 \times \text{miR-486-5p}) + (0.47157 \times \text{miR-498}) + (0.35716 \times \text{miR-6088}) + (0.09762 \times$
164 $\text{miR-6872-3p}) + 13.9039$ and model TFIp ≥ 6 months: $\exp Y / (1 + \exp Y) | Y = (0.04331 \times$
165 $\text{miR-4708-3p}) + 1.0617$ and model TFIp ≥ 12 months: $\exp Y / (1 + \exp Y) | Y = (-0.0426 \times$
166 $\text{miR-3141}) + (0.01861 \times \text{miR-3928-3p}) + (0.0129 \times \text{miR-6766-5p}) + (0.0094 \times \text{miR-7108-3p}) +$
167 0.31159 , and model TFIp ≥ 12 months: $\exp Y / (1 + \exp Y) | Y = (-0.0125433 \times \text{miR-1181}) +$
168 $(0.1067349 \times \text{miR-1254}) + (0.0015947 \times \text{miR-1268b}) + (-0.3771727 \times \text{miR-187-5p}) + (0.0360527 \times$
169 $\text{miR-191-5p}) + (-0.0984009 \times \text{miR-3141}) + (0.0233745 \times \text{miR-3195}) + (-0.5606837 \times \text{miR-3197}) +$
170 $(0.2415774 \times \text{miR-320a}) + (0.1046963 \times \text{miR-342-5p}) + (0.0502296 \times \text{miR-3928-3p}) + (0.0009486$
171 $\times \text{miR-422a}) + (0.0050783 \times \text{miR-4419b}) + (0.05179 \times \text{miR-4429}) + (0.4470169 \times \text{miR-4447}) +$
172 $(0.0210486 \times \text{miR-4449}) + (-0.9951068 \times \text{miR-4463}) + (-0.0335096 \times \text{miR-4484}) + (0.0152364 \times$
173 $\text{miR-4515}) + (0.0870314 \times \text{miR-4640-5p}) + (0.2338915 \times \text{miR-4675}) + (0.0864322 \times \text{miR-486-5p})$
174 $+ (0.5827542 \times \text{miR-557}) + (0.0782236 \times \text{miR-6088}) + (-0.1712249 \times \text{miR-642a-3p}) + (0.1380852$
175 $\times \text{miR-6766-3p}) + (-0.3991616 \times \text{miR-6799-5p}) + (-0.2738122 \times \text{miR-6808-5p}) + (0.0531576 \times$

176 miR-6842-5p) + (-0.5248665 × miR-6858-5p) + (0.033589 × miR-7108-3p) + (-0.2512049 ×
177 miR-718) + (-0.5161003 × miR-8089) + (-0.1219326 × miR-887-3p) + (0.0626341 × miR-939-5p)
178 + 19.9189978. The AUC of most appropriate predictive models for each model was as follows:
179 model TFIP > 1 month: 0.944 (95% CI: 0.896–0.992) for the group with TFIP > 1 month, model
180 TFIP ≥ 6 months: 0.637 (95% CI: 0.526–0.748) for the group with TFIP ≥ 6 months, model TFIP ≥
181 12 months: 0.705 (95% CI: 0.622–0.787) for the group with TFIP ≥ 12 months, and model TFIP ≥ 36
182 months: 0.938 (95% CI: 0.891–0.985) for the model with TFIP ≥ 36 months (Figure 2).

183 **Further potentials for predictive models**

184 Each model was applied to all subgroups and AUCs were calculated. Model TFIP > 1 month: AUC
185 of 0.683 for the group with TFIP ≥ 6 months, 0.603 for TFIP ≥ 12 months, and 0.618 for TFIP ≥ 36
186 months. Model TFIP ≥ 6 months: 0.631 for TFIP > 1 month, 0.570 for TFIP 12 ≥ months, and 0.563
187 for TFIP ≥ 36 months. Model TFIP ≥ 12 months: 0.757 for > 1 month, 0.698 for TFIP 6 ≥ months,
188 and 0.659 for TFIP ≥ 36 months. Model TFIP ≥ 36 months: 0.624 for > 1 month, 0.641 for TFIP 6 ≥
189 months, and 0.645 for TFIP ≥ 12 months (Supplementary Table 2). The predictive models for each
190 TFIP group were re-evaluated by dividing each group into those with TFIP shorter and longer than
191 the cutoff value. As shown in Figure 3A, there was a significant difference in each group ($p = 0.001$
192 in model TFIP > 1 month, $p = 0.013$ in model TFIP ≥ 6 months, $p < 0.001$ in model TFIP ≥ 12
193 months, and $p < 0.001$ in model TFIP ≥ 36 months) (Figure 3A, Supplementary Figure 2A). Upon
194 examining the model score transition for each patient, we observed a tendency of decreasing model
195 score when the actual TFIP was lower than the predicted TFIP (Figure 3B).

196 **Reassessment of the predictive model**

197 Pearson's correlation coefficients were calculated between TFIP and model score for each model.
198 TFIP was positively correlated with all models ($r = 0.170$ in model TFIP > 1 month, $r = 0.047$ in
199 model TFIP ≥ 6 months, $r = 0.256$ in model TFIP ≥ 12 months, and $r = 0.630$ in model TFIP ≥ 36
200 months) (Supplementary Figure 2A). Kaplan–Meier curves were constructed after stratifying patients

201 into high and low groups based on the cutoff value of each model score. The Kaplan–Meier curves
202 indicated that patients with a high model score had significantly longer TFIp than those with a low
203 model score ($p = 0.006$ in model TFIp > 1 month, $p = 0.003$ in model TFIp \geq 12 months, and $p <$
204 0.001 in model TFIp \geq 36 months) (Supplementary Figure 2B). Therefore, the three models have the
205 potential to predict early recurrence, regardless of each cutoff value.

206 **Discussion**

207 Accurate prediction of platinum response is fundamentally important in the clinical management of
208 patients with HGSOc. Previous studies have explored the efficacy of platinum chemotherapy by
209 categorizing patients as those who were platinum-sensitive and those who were platinum-resistant
210 based on a TFIp of 6 months [23, 24]. In the present study, we evaluated the expected TFIp before
211 platinum chemotherapy. The AUC values for model TFIp > 1 month and model TFIp \geq 36 months
212 were 0.944 and 0.938, respectively. The inclusion of circulating miRNA profiles in these analyses
213 demonstrated their ability in accurately predicting TFIp.

214 The mechanisms underlying platinum chemotherapy resistance in patients with HGSOc
215 have been extensively evaluated [25-28]. Platinum resistance is not straightforward and is considered
216 a complex biologic process. Therefore, the combination of factors, rather than a single factor, is a
217 reasonable approach to develop biomarkers. In the present study, the miRNAs selected as predictive
218 factors were different and multiple in each model, which may reflect platinum-resistant and
219 -sensitive pathologies. Model TFIp \geq 12 months appeared to be versatile, with an AUC \geq 0.69 for all
220 subgroups, but model TFIp > 1 month for the group with TFIp > 1 month and model TFIp \geq 6
221 months for TFIp \geq 6 months were the most appropriate, each with an AUC of \geq 0.9. The miRNA with
222 the strongest negative impact in model TFIp > 1 month was miR-4739. With demonstrated
223 involvement in the VEGFA/PI3K/AKT pathway, miR-4739 has been reported to play an
224 antioncogenic role in pancreatic cancer [29]. The miRNA with the strongest impact in model TFIp \geq
225 6 months was miR-4708-3p. According to miRDB, one of the targets of miR-4708-3p is interleukin

226 22, which has been previously reported to be involved in chemotherapy resistance in lung and breast
227 cancers [30-32]. The miRNA with the strongest impact in model TFIp ≥ 12 months was miR-3141,
228 which directly targets transforming growth factor- β , which has demonstrated roles in platinum
229 response in ovarian cancer [33-35].

230 Currently, there is not one standard definition for therapeutic response, although biomarkers
231 to predict therapeutic response have been investigated in ovarian cancer. In clinical trials, the typical
232 primary endpoints are indicators such as overall and progression-free survival and response rate.
233 Indicators that might define platinum treatment response in ovarian cancer include TFIp, response
234 rate, and progression-free survival [24, 36, 37]. Biomarkers that can predict platinum response
235 should be able to predict TFIp in first-line therapy because TFIp is expected. Second- or third-line
236 chemotherapy might provide TFIp; however, recurrence and progression might still occur during
237 platinum chemotherapy. Therefore, biomarkers predicting platinum response and recurrence in
238 second- or third-line chemotherapy should be defined by TFIp or progression-free survival from
239 treatment initiation for recurrence. After fourth-line therapy, the risk of recurrence and progression
240 during platinum chemotherapy is even higher and predictive biomarkers for platinum response might
241 be defined by the duration of continued platinum therapy. Ovarian cancer is unique as patients are
242 repeatedly administered platinum chemotherapy, even in cases of relapse, while good response to
243 platinum chemotherapy is expected. In the present study, we selected TFIp as an indicator of
244 predictive biomarkers for platinum response as platinum was administered as first-line therapy.
245 Biomarkers that can predict treatment response should be defined according to the specific line of
246 treatment.

247 The present study has several limitations. First, our results were based on dataset reanalysis
248 and validation experiments using patients with recurrent cancer could not be conducted. Second, we
249 did not include patients who received bevacizumab or PARPi as first-line therapy; therefore, whether
250 the predictive models can be applied to these patients remains unclear. Circulating miRNAs can be

251 upregulated or downregulated by bevacizumab or PARPi [38, 39]. Further studies with larger,
252 independent groups are needed to determine predictive biomarkers for response to platinum in
253 combination with bevacizumab or PARPi. Third, although the expression of miRNAs in ovarian
254 cancer cell lines was considered, the origin of the circulating miRNAs measured in the present study
255 was unclear. Furthermore, the function of miRNAs in HGSOc should be evaluated in future studies.

256 In conclusion, we identified a circulating miRNA profile that predicted platinum response in
257 HGSOc before platinum chemotherapy. Accurate prediction of treatment response prior to initiation
258 can assist in determining appropriate treatment strategies, such as avoiding unnecessary treatments or
259 choosing additional treatments. Prospective studies are warranted to evaluate circulating miRNA
260 analysis for the translation of miRNA profiling into clinical care.

261

262 **Author Contribution**

263 Study concept and design: Kazuhiro Suzuki., Akira Yokoi.

264 Provision of materials or patients: Kazuhiro Suzuki., Akira Yokoi., Kosuke Yoshida., Mitsuya
265 Ishikawa., Tomoyasu Kato.

266 Analysis and interpretation of data: Kazuhiro Suzuki., Akira Yokoi., Juntaro Matsuzaki., Kosuke
267 Yoshida.

268 Manuscript writing: Kazuhiro Suzuki., Akira Yokoi., Yoshida Kosuke., Juntaro Matsuzaki.

269 Critical review of the manuscript: All authors contributed.

270 Final approval of manuscript: All authors contributed.

271

272 **Conflict of Interest**

273 None of the authors reported a conflict of interest

274

275 **Acknowledgment**

276 No funding support of any kind was received for this study.

277

278 **References**

- 279 [1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer
280 Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185
281 Countries. *CA Cancer J Clin.* 2021;71:209-49.
- 282 [2] Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. *Lancet.*
283 2019;393:1240-53.
- 284 [3] Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. *Cancer Biol Med.*
285 2017;14:9-32.
- 286 [4] Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al.
287 Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr*
288 *Canc Netw.* 2021;19:191-226.
- 289 [5] Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marme F, Lindemann K, et al. Maintenance
290 olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated
291 with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. *Ann Oncol.* 2023.
- 292 [6] Takamatsu S, Nakai H, Yamaguchi K, Hamanishi J, Mandai M, Matsumura N. Time-Dependent
293 Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer. *JAMA Netw Open.*
294 2023;6:e2326834.
- 295 [7] Pujade-Lauraine E, Alexandre J. Update of randomized trials in recurrent disease. *Ann Oncol.*
296 2011;22 Suppl 8:viii61-viii4.
- 297 [8] Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab
298 combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA
299 open-label randomized phase III trial. *J Clin Oncol.* 2014;32:1302-8.
- 300 [9] Arend RC, Monk BJ, Shapira-Frommer R, Haggerty AF, Alvarez EA, Amit A, et al. Ofranergene

- 301 Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer:
302 Randomized Controlled Phase III Trial (OVAL Study/GOG 3018). *J Clin Oncol*. 2023;JCO2202915.
- 303 [10] van der Burg ME, Vergote I, Onstenk W, Boere IA, Leunen K, van Montfort CA, et al.
304 Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated
305 treatment in patients with platinum-resistant ovarian cancer. *Eur J Cancer*. 2013;49:1254-63.
- 306 [11] Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, et al. Weekly
307 paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with
308 resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs
309 Nationaux pour l'Etude des Cancers Ovariens (GINECO). *Ann Oncol*. 2012;23:346-52.
- 310 [12] Ambros V. The functions of animal microRNAs. *Nature*. 2004;431:350-5.
- 311 [13] Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer*.
312 2006;6:259-69.
- 313 [14] Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer
314 of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*.
315 2007;9:654-9.
- 316 [15] Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker
317 for cancer diagnosis and prognosis. *Cancer Sci*. 2010;101:2087-92.
- 318 [16] Yokoi A, Ochiya T. Exosomes and extracellular vesicles: Rethinking the essential values in
319 cancer biology. *Semin Cancer Biol*. 2021;74:79-91.
- 320 [17] Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, et al. Integrated
321 extracellular microRNA profiling for ovarian cancer screening. *Nat Commun*. 2018;9:4319.
- 322 [18] Yoshida K, Yokoi A, Matsuzaki J, Kato T, Ochiya T, Kajiyama H, et al. Extracellular microRNA
323 profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma. *Cancer Sci*.
324 2021;112:4977-86.
- 325 [19] Suzuki K, Yokoi A, Yoshida K, Kato T, Ochiya T, Yamamoto Y, et al. Preoperative serum

- 326 microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma. *J Gynecol Oncol.*
327 2023;34:e34.
- 328 [20] Okuno K, Kandimalla R, Mendiola M, Balaguer F, Bujanda L, Fernandez-Martos C, et al. A
329 microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant
330 therapy in stage II and III colorectal cancer. *Mol Cancer.* 2023;22:13.
- 331 [21] Wu A, Yen R, Grasedieck S, Lin H, Nakamoto H, Forrest DL, et al. Identification of
332 multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic
333 myeloid leukemia at diagnosis. *Leukemia.* 2023.
- 334 [22] Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep
335 sequencing data. *Nucleic Acids Res.* 2014;42:D68-73.
- 336 [23] Yu X, Zhang X, Wang G, Wang B, Ding Y, Zhao J, et al. miR-206 as a prognostic and sensitivity
337 biomarker for platinum chemotherapy in epithelial ovarian cancer. *Cancer Cell Int.* 2020;20:534.
- 338 [24] Compadre AJ, van Biljon LN, Valentine MC, Llop-Guevara A, Graham E, Fashemi B, et al.
339 RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer.
340 *Clin Cancer Res.* 2023;29:2466-79.
- 341 [25] Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the
342 anticancer drug cisplatin with a copper chelator. *Cancer Cell.* 2010;17:574-83.
- 343 [26] Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, et al. Ovarian cancer stem
344 cell-like side populations are enriched following chemotherapy and overexpress EZH2. *Mol Cancer*
345 *Ther.* 2011;10:325-35.
- 346 [27] Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, et al. Cisplatin treatment of
347 primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal
348 stem cell-like profile. *J Cell Biochem.* 2011;112:2850-64.
- 349 [28] Belanger F, Fortier E, Dube M, Lemay JF, Buisson R, Masson JY, et al. Replication Protein A
350 Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in

- 351 Ovarian Cancer Cells. *Cancer Res.* 2018;78:5561-73.
- 352 [29] Zheng D, Huang X, Peng J, Zhuang Y, Li Y, Qu J, et al. CircMYOF triggers progression and
353 facilitates glycolysis via the VEGFA/PI3K/AKT axis by absorbing miR-4739 in pancreatic ductal
354 adenocarcinoma. *Cell Death Discov.* 2021;7:362.
- 355 [30] Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets.
356 *Nucleic Acids Res.* 2020;48:D127-D31.
- 357 [31] Khosravi N, Caetano MS, Cumpian AM, Unver N, De la Garza Ramos C, Noble O, et al. IL22
358 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of
359 Stemness Properties. *Cancer Immunol Res.* 2018;6:788-97.
- 360 [32] Wang S, Yao Y, Yao M, Fu P, Wang W. Interleukin-22 promotes triple negative breast cancer
361 cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
362 *Biochem Biophys Res Commun.* 2018;503:1605-9.
- 363 [33] Wu D, Zhou J, Tan M, Zhou Y. LINC01116 regulates proliferation, migration, and apoptosis of
364 keloid fibroblasts by the TGF-beta1/SMAD3 signaling via targeting miR-3141. *Anal Biochem.*
365 2021;627:114249.
- 366 [34] Zhu H, Gu X, Xia L, Zhou Y, Bouamar H, Yang J, et al. A Novel TGFbeta Trap Blocks
367 Chemotherapeutics-Induced TGFbeta1 Signaling and Enhances Their Anticancer Activity in
368 Gynecologic Cancers. *Clin Cancer Res.* 2018;24:2780-93.
- 369 [35] Gagno S, Poletto E, Bartoletti M, Quartuccio L, Romualdi C, Garziera M, et al. A TGF-beta
370 associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian
371 cancer. *Gynecol Oncol.* 2020;156:233-42.
- 372 [36] Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, et al.
373 Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or
374 BRCA2 mutations. *Gynecol Oncol.* 2021;160:786-92.
- 375 [37] You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, et al. CA-125 ELIMination

376 Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results
377 from the Phase II CHIVA Trial. Clin Cancer Res. 2020;26:4625-32.

378 [38] Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, et al.
379 miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy
380 treatment in breast cancer. Mol Oncol. 2019;13:2278-96.

381 [39] Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, et al. Platinum and PARP Inhibitor
382 Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep.
383 2016;14:429-39.

384

385 **Figure legends**

386 **Figure 1.**

387 Selection of patients and study design.

388 Flowchart of patients' selection. We identified a total of 442 patients with ovarian tumors with
389 preoperative serum microRNA profiles. Among them, 180 patients were diagnosed with high-grade
390 serous ovarian carcinoma. Finally, 180 patients were assessed in this study, after excluding 27
391 patients with stage I–II cancer, insufficient clinical information, and low-quality samples.

392 **Figure 2.** ROC curves for each Model.

393 ROC curves for prediction of TFIp by models using LASSO logistic regression analysis. The green
394 colored area indicates the 95% confidence interval region. The details of the predictive model are
395 shown in Supplementary Table 1.

396 **Figure 3.** Development of the predictive TFIp models

397 **A.** Dot plot for each Model. Patients were stratified based on the TFIp. *p* values were calculated by
398 Welch's *t*-test.

399 **B.** Model values for each in the same patient. Colored values indicate representative cases.

400

401 **Supplementary figure legends**

402 **Supplementary figure 1.**

403 Time course of ovarian cancer treatment and definition of treatment-free interval of platinum

404 Abbreviation: Ope, operation.

405 **Supplementary figure 2.**

406 A. Dot plot for each model. Dotted lines indicate linear regression model. R values were calculated

407 using Pearson's correlation coefficient.

408 B. Events over time were evaluated based on predictive models.

409 Kaplan–Meier curves showing patients stratified into high and low groups by each model with

410 cutoffs based on Youden index. *p* values were calculated using the generalized Wilcoxon test

Table 1

Clinical characteristics of 153 patients with high-grade serous carcinoma grouped according to TFIP.

	Number of patients (%)					p-value
	Total (n = 153)	TFIP > 1 months (n = 143)	TFIP ≥ 6 months (n = 122)	TFIP ≥ 12 months (n = 84)	TFIP ≥ 36 months (n = 30)	
Age, years—median (range)	60.2 (34–82)	60.3 (34–82)	60.5 (34–82)	59.21 (34–82)	56.8 (34–78)	0.418
FIGO stage						0.981
IIIC	96 (62.7)	92 (64.3)	81 (66.4)	56 (66.7)	18 (60.0)	
IVA	11 (7.2)	10 (7.0)	9 (7.4)	8 (9.5)	3 (10.0)	
IVB	46 (30.1)	41 (28.7)	32 (26.2)	20 (23.8)	9 (30.0)	
Neoadjuvant chemotherapy						0.255
Yes	98 (62.7)	88 (61.5)	75 (61.5)	47 (56.0)	13 (43.3)	
No	55 (35.9)	55 (38.5)	47 (38.5)	37 (44.0)	17 (56.7)	
Surgery						0.229
Complete	9 (5.9)	9 (6.3)	8 (6.6)	7 (8.3)	6 (20.0)	
Optimal	120 (78.4)	115 (80.4)	99 (81.1)	70 (83.3)	21 (70.0)	
Sub-optimal	24 (15.7)	19 (13.3)	15 (12.3)	7 (8.3)	3 (10.0)	
Recurrence						< 0.001
Yes	132 (86.3)	122 (85.3)	101 (82.8)	63 (75.0)	10 (33.3)	
No	21 (13.7)	21 (14.7)	21 (17.2)	21 (25.0)	20 (66.7)	
TFIP, months—median (range)	22.6 (0–130)	24.18 (2–130)	27.82 (6–130)	36.49 (12–130)	65.70 (36–130)	< 0.001
PFS, months—median (range)	28.3 (4–136)	29.76 (5–136)	33.38 (10–136)	42.35 (16–136)	72.50 (40–136)	< 0.001
OS, months—median (range)	55.8 (8–142)	57.84 (8–142)	64.16 (13–142)	73.90 (22–142)	86.03 (49–142)	< 0.001

Note: Data are shown as n (%) unless otherwise noted.

Abbreviation: PFS, progression-free survival. OS, overall survival.

Table2.

Discrimination accuracy of each diagnostic model

Model No.	TFI _p	miRNAs (n)	Sensitivity	Specificity	Accuracy	AUC	(95%CI)	ρ (DeLong's test)	
1-1	>1 month	8	0.755	1.000	0.771	0.903	(0.832 – 0.974)		
1-2	>1 month	9	0.783	1.000	0.797	0.928	(0.871 – 0.985)	0.041	(vs. 1-1)
1-3 (Model TFI_p > 1 month)	>1 month	10	0.818	1.000	0.830	0.944	(0.896 – 0.992)	0.047	(vs. 1-2)
1-4	>1 month	11	0.818	1.000	0.830	0.961	(0.921 – 1.000)	0.061	(vs. 1-3)
1-5	>1 month	13	0.951	0.900	0.948	0.967	(0.930 – 1.000)	0.179	(vs. 1-4)
1-6	>1 month	14	0.986	0.900	0.980	0.980	(0.949 – 1.000)	0.509	(vs. 1-5)
1-7	>1 month	15	0.993	0.900	0.987	0.985	(0.959 – 1.000)	0.219	(vs. 1-6)
1-8	>1 month	17	0.993	0.900	0.987	0.986	(0.963 – 1.000)	0.414	(vs. 1-7)
1-9	>1 month	18	0.937	1.000	0.941	0.990	(0.976 – 1.000)	0.436	(vs. 1-8)
6-1 (Model TFI_p ≥ 6 months)	≥6 months	1	0.467	0.774	0.529	0.637	(0.526 – 0.748)		
12-1 (Model TFI_p ≥ 12 months)	≥12 months	4	0.706	0.588	0.654	0.705	(0.622 – 0.787)		
12-2	≥12 months	5	0.741	0.574	0.667	0.713	(0.632 – 0.794)	0.155	(vs. 12-1)
12-3	≥12 months	6	0.647	0.677	0.660	0.721	(0.642 – 0.801)	0.059	(vs. 12-2)
12-4	≥12 months	7	0.894	0.441	0.693	0.726	(0.647 – 0.806)	0.252	(vs. 12-3)
12-5	≥12 months	8	0.753	0.588	0.698	0.736	(0.658 – 0.815)	0.110	(vs. 12-4)
36-1	≥36 months	25	0.867	0.829	0.837	0.901	(0.842 – 0.960)		(vs. 36-14)
36-2	≥36 months	26	0.867	0.878	0.876	0.914	(0.859 – 0.970)	0.007	(vs. 36-15)
36-3	≥36 months	29	0.900	0.854	0.863	0.917	(0.862 – 0.971)	0.046	(vs. 36-16)
36-4	≥36 months	30	0.900	0.862	0.870	0.920	(0.867 – 0.974)	0.014	(vs. 36-17)
36-5	≥36 months	31	0.900	0.870	0.876	0.926	(0.875 – 0.978)	0.005	(vs. 36-18)
36-6	≥36 months	33	0.900	0.894	0.895	0.931	(0.881 – 0.980)	0.020	(vs. 36-19)
36-7 (Model TFI_p ≥ 36 months)	≥36 months	36	0.900	0.894	0.895	0.938	(0.891 – 0.985)	0.009	(vs. 36-20)

Figure 1




Figure 2







Figure 3




Supplementary figure 1




Supplementary figure 2

A



B



Supplementary Table1. Detail of predictive model

Model No.	Predictive model Y
1-1	$(-0.08022 \times \text{miR-1228-5p}) + (-0.16169 \times \text{miR-1273g-3p}) + (0.23871 \times \text{miR-3917}) + (-0.0793 \times \text{miR-3940-5p}) + (-0.72774 \times \text{miR-4739}) + (0.3835 \times \text{miR-498}) + (0.01805 \times \text{miR-6088}) + (0.04429 \times \text{miR-6872-3p}) + 10.07757$
1-2	$(-0.305235 \times \text{miR-1228-5p}) + (-0.2308 \times \text{miR-1273g-3p}) + (0.271838 \times \text{miR-3917}) + (-0.13299 \times \text{miR-3940-5p}) + (0.005181 \times \text{miR-4708-3p}) + (-0.89869 \times \text{miR-4739}) + (0.435498 \times \text{miR-498}) + (0.231217 \times \text{miR-6088}) + (0.085698 \times \text{miR-6872-3p}) + 12.543835$
1-3 (Model TF1p > 1 month)	$(-0.43074 \times \text{miR-1228-5p}) + (-0.2713 \times \text{miR-1273g-3p}) + (0.2881 \times \text{miR-3917}) + (-0.15449 \times \text{miR-3940-5p}) + (0.03679 \times \text{miR-4708-3p}) + (-1.00381 \times \text{miR-4739}) + (-0.0285 \times \text{miR-486-5p}) + (0.47157 \times \text{miR-498}) + (0.35716 \times \text{miR-6088}) + (0.09762 \times \text{miR-6872-3p}) + 13.9039$
1-4	$(-0.58016 \times \text{miR-1228-5p}) + (-0.307222 \times \text{miR-1273g-3p}) + (0.330061 \times \text{miR-3917}) + (-0.171047 \times \text{miR-3940-5p}) + (0.092346 \times \text{miR-4708-3p}) + (-1.1506 \times \text{miR-4739}) + (-0.142806 \times \text{miR-486-5p}) + (0.526739 \times \text{miR-498}) + (0.007233 \times \text{miR-6087}) + (0.525026 \times \text{miR-6088}) + (0.107553 \times \text{miR-6872-3p}) + 15.494438$
1-5	$(-0.646803 \times \text{miR-1228-5p}) + (-0.313229 \times \text{miR-1273g-3p}) + (0.030311 \times \text{miR-371a-5p}) + (0.34458 \times \text{miR-3917}) + (-0.165331 \times \text{miR-3940-5p}) + (0.002726 \times \text{miR-4449}) + (0.110589 \times \text{miR-4708-3p}) + (-1.211764 \times \text{miR-4739}) + (-0.178796 \times \text{miR-486-5p}) + (0.545045 \times \text{miR-498}) + (0.032721 \times \text{miR-6087}) + (0.569194 \times \text{miR-6088}) + (0.11015 \times \text{miR-6872-3p}) + 15.78128$

- 1-6 $(-0.90035 \times \text{miR-1228-5p}) + (-0.33003 \times \text{miR-1273g-3p}) + (-0.01715 \times \text{miR-17-3p}) + (0.13348 \times \text{miR-371a-5p}) + (0.36831 \times \text{miR-3917}) + (0.05396 \times \text{miR-3928-3p}) + (-0.20548 \times \text{miR-3940-5p}) + (0.15664 \times \text{miR-4449}) + (0.16038 \times \text{miR-4708-3p}) + (-1.45235 \times \text{miR-4739}) + (-0.27004 \times \text{miR-486-5p}) + (0.57565 \times \text{miR-498}) + (0.74862 \times \text{miR-6088}) + (0.11426 \times \text{miR-6872-3p}) + 18.19444$
- 1-7 $(-0.002713 \times \text{miR-1181}) + (-0.991055 \times \text{miR-1228-5p}) + (-0.328202 \times \text{miR-1273g-3p}) + (-0.037427 \times \text{miR-17-3p}) + (0.169809 \times \text{miR-371a-5p}) + (0.377633 \times \text{miR-3917}) + (0.079125 \times \text{miR-3928-3p}) + (-0.222452 \times \text{miR-3940-5p}) + (0.196208 \times \text{miR-4449}) + (0.17659 \times \text{miR-4708-3p}) + (-1.538496 \times \text{miR-4739}) + (-0.292685 \times \text{miR-486-5p}) + (0.58726 \times \text{miR-498}) + (0.80589 \times \text{miR-6088}) + (0.112803 \times \text{miR-6872-3p}) + 19.075818$
- 1-8 $(-0.009675 \times \text{miR-1181}) + (-1.050908 \times \text{miR-1228-5p}) + (-0.331264 \times \text{miR-1273g-3p}) + (-0.0542 \times \text{miR-17-3p}) + (0.027084 \times \text{miR-3158-5p}) + (0.19372 \times \text{miR-371a-5p}) + (0.383034 \times \text{miR-3917}) + (0.111428 \times \text{miR-3928-3p}) + (-0.23688 \times \text{miR-3940-5p}) + (0.217287 \times \text{miR-4449}) + (0.188668 \times \text{miR-4708-3p}) + (-1.673817 \times \text{miR-4739}) + (-0.317227 \times \text{miR-486-5p}) + (0.596774 \times \text{miR-498}) + (0.854739 \times \text{miR-6088}) + (-0.007404 \times \text{miR-671-5p}) + (0.110257 \times \text{miR-6872-3p}) + 20.442601$
- 1-9 $(-0.022898 \times \text{miR-1181}) + (-1.163292 \times \text{miR-1228-5p}) + (-0.33282 \times \text{miR-1273g-3p}) + (-0.088704 \times \text{miR-17-3p}) + (0.073399 \times \text{miR-3158-5p}) + (0.245542 \times \text{miR-371a-5p}) + (0.397722 \times \text{miR-3917}) + (0.176185 \times \text{miR-3928-3p}) + (-0.259566 \times \text{miR-3940-5p}) + (0.247176 \times \text{miR-4449}) + (0.007695 \times \text{miR-4675}) + (0.211683 \times \text{miR-4708-3p}) + (-1.931075 \times \text{miR-4739}) + (-0.363093 \times \text{miR-486-5p}) + (0.61721 \times \text{miR-498}) + (0.948609 \times \text{miR-6088}) + (-0.027716 \times \text{miR-671-5p}) + (0.103336 \times \text{miR-6872-3p}) + 22.921317$
- 6-1 (Model TFIP ≥ 6 months) $(0.04331 \times \text{miR-4708-3p}) + 1.0617$

- 12-1 (**Model TFIP** $(-0.0426 \times \text{miR-3141}) + (0.01861 \times \text{miR-3928-3p}) + (0.0129 \times \text{miR-6766-5p}) + (0.0094 \times \text{miR-7108-3p}) + 0.31159$
 ≥ 12 months)
- 12-2 $(0.005506 \times \text{miR-1254}) + (-0.233162 \times \text{miR-3141}) + (0.108505 \times \text{miR-3928-3p}) + (0.052679 \times \text{miR-6766-5p}) + (0.046921 \times \text{miR-7108-3p}) + 0.771309$
- 12-3 $(0.024523 \times \text{miR-1254}) + (-0.370958 \times \text{miR-3141}) + (0.158208 \times \text{miR-3928-3p}) + (0.074012 \times \text{miR-6766-5p}) + (-0.008133 \times \text{miR-6869-5p}) + (0.073977 \times \text{miR-7108-3p}) + 1.267906$
- 12-4 $(0.030583 \times \text{miR-1254}) + (-0.414682 \times \text{miR-3141}) + (0.174476 \times \text{miR-3928-3p}) + (-0.002631 \times \text{miR-6722-3p}) + (0.080808 \times \text{miR-6766-5p}) + (-0.026614 \times \text{miR-6869-5p}) + (0.085647 \times \text{miR-7108-3p}) + 1.635997$
- 12-5 $(0.041917 \times \text{miR-1254}) + (-0.492179 \times \text{miR-3141}) + (0.201249 \times \text{miR-3928-3p}) + (0.003775 \times \text{miR-4322}) + (-0.052872 \times \text{miR-6722-3p}) + (0.098461 \times \text{miR-6766-5p}) + (-0.05535 \times \text{miR-6869-5p}) + (0.105975 \times \text{miR-7108-3p}) + 2.590153$
- 36-1 $(-0.0085052 \times \text{miR-1254}) + (-0.2186654 \times \text{miR-187-5p}) + (-0.0117764 \times \text{miR-1908-3p}) + (0.0192129 \times \text{miR-191-5p}) + (-0.0818024 \times \text{miR-3141}) + (-0.4142278 \times \text{miR-3197}) + (0.1690961 \times \text{miR-320a}) + (0.0526361 \times \text{miR-342-5p}) + (0.0145941 \times \text{miR-4429}) + (0.3025396 \times \text{miR-4447}) + (-0.3635017 \times \text{miR-4463}) + (0.0458145 \times \text{miR-4515}) + (0.0542341 \times \text{miR-4675}) + (0.0004475 \times \text{miR-4732-5p}) + (0.0496912 \times \text{miR-486-5p}) + (0.2732072 \times \text{miR-557}) + (-0.0545019 \times \text{miR-642a-3p}) + (0.0599133 \times \text{miR-6766-3p}) + (-0.1072596 \times \text{miR-6799-5p}) + (-0.0986669 \times \text{miR-6808-5p}) + (-0.4353737 \times \text{miR-6858-5p}) + (-0.0400214 \times \text{miR-718}) + (-0.3317855 \times \text{miR-8089}) + (-0.0853479 \times \text{miR-887-3p}) + 11.2233496$

- 36-2 (-0.0100718xmiR-1254) + (-0.2774778xmiR-187-5p) + (0.0235554xmiR-191-5p) + (-0.0858186xmiR-3141) + (-0.4645236xmiR-3197) + (0.1909219xmiR-320a) + (0.0730775xmiR-342-5p) + (0.038733xmiR-4429) + (0.3572965xmiR-4447) + (0.0018236xmiR-4449) + (-0.566197xmiR-4463) + (0.0426433xmiR-4515) + (0.139225xmiR-4675) + (0.0015923xmiR-4732-5p) + (0.060029xmiR-486-5p) + (0.3794857xmiR-557) + (0.0006165xmiR-6088) + (-0.0948298xmiR-642a-3p) + (0.0941779xmiR-6766-3p) + (-0.1842586xmiR-6799-5p) + (-0.1423826xmiR-6808-5p) + (-0.4693842xmiR-6858-5p) + (-0.1065337xmiR-718) + (-0.4048481xmiR-8089) + (-0.0975639xmiR-887-3p) + 14.2793853
- 36-3 (-0.010512xmiR-1254) + (-0.296032xmiR-187-5p) + (0.025459xmiR-191-5p) + (-0.085324xmiR-3141) + (-0.480216xmiR-3197) + (0.197352xmiR-320a) + (0.07997xmiR-342-5p) + (0.008677xmiR-3928-3p) + (0.045585xmiR-4429) + (0.373793xmiR-4447) + (0.005308xmiR-4449) + (-0.629153xmiR-4463) + (0.040963xmiR-4515) + (0.001092xmiR-4640-5p) + (0.161587xmiR-4675) + (0.001617xmiR-4732-5p) + (0.06312xmiR-486-5p) + (0.412694xmiR-557) + (0.010712xmiR-6088) + (-0.108938xmiR-642a-3p) + (0.102524xmiR-6766-3p) + (-0.211281xmiR-6799-5p) + (-0.161989xmiR-6808-5p) + (0.003912xmiR-6842-5p) + (-0.48001xmiR-6858-5p) + (-0.128392xmiR-718) + (-0.424643xmiR-8089) + (-0.101338xmiR-887-3p) + 15.160137
- 36-4 (-0.0108976xmiR-1254) + (-0.313461xmiR-187-5p) + (0.0274867xmiR-191-5p) + (-0.0877817xmiR-3141) + (-0.4953478xmiR-3197) + (0.2058604xmiR-320a) + (0.0849152xmiR-342-5p) + (0.0191089xmiR-3928-3p) + (0.0006009xmiR-4419b) + (0.0505798xmiR-4429) + (0.3888059xmiR-4447) + (0.008254xmiR-4449) + (-0.702695xmiR-4463) + (0.0379672xmiR-4515) + (0.0200086xmiR-4640-5p) + (0.1783874xmiR-4675) + (0.0007739xmiR-4732-5p) + (0.0678916xmiR-486-5p) + (0.4450908xmiR-557) + (0.0250757xmiR-6088) + (-0.1206386xmiR-642a-3p) + (0.1110271xmiR-6766-3p) + (-0.2438217xmiR-6799-5p) + (-0.1850382xmiR-6808-5p) +

$$(0.0141535 \times \text{miR-6842-5p}) + (-0.4881161 \times \text{miR-6858-5p}) + (-0.1534442 \times \text{miR-718}) + (-0.4433555 \times \text{miR-8089}) + (-0.1063541 \times \text{miR-887-3p}) + 16.0608247$$

36-5

$$\begin{aligned} & (-0.011304 \times \text{miR-1254}) + (-0.330556 \times \text{miR-187-5p}) + (0.029674 \times \text{miR-191-5p}) + (-0.090643 \times \text{miR-3141}) + \\ & (-0.510819 \times \text{miR-3197}) + (0.21427 \times \text{miR-320a}) + (0.0897 \times \text{miR-342-5p}) + (0.029023 \times \text{miR-3928-3p}) + (0.003306 \times \text{miR-4419b}) \\ & + (0.053975 \times \text{miR-4429}) + (0.403336 \times \text{miR-4447}) + (0.011158 \times \text{miR-4449}) + (-0.774378 \times \text{miR-4463}) + (0.034354 \times \text{miR-4515}) + \\ & (0.037603 \times \text{miR-4640-5p}) + (0.195169 \times \text{miR-4675}) + (0.072194 \times \text{miR-486-5p}) + (0.4778 \times \text{miR-557}) + (0.039272 \times \text{miR-6088}) + \\ & (-0.132742 \times \text{miR-642a-3p}) + (0.118471 \times \text{miR-6766-3p}) + (-0.279327 \times \text{miR-6799-5p}) + (-0.208812 \times \text{miR-6808-5p}) + \\ & (0.023642 \times \text{miR-6842-5p}) + (-0.497048 \times \text{miR-6858-5p}) + (0.001925 \times \text{miR-6877-5p}) + (-0.17823 \times \text{miR-718}) + \\ & (-0.461239 \times \text{miR-8089}) + (-0.111737 \times \text{miR-887-3p}) + (0.004446 \times \text{miR-939-5p}) + 16.976658 \end{aligned}$$

36-6

$$\begin{aligned} & (-0.011751 \times \text{miR-1254}) + (-0.347334 \times \text{miR-187-5p}) + (0.032074 \times \text{miR-191-5p}) + (-0.0963 \times \text{miR-3141}) + (-0.527889 \times \text{miR-3197}) \\ & + (0.223442 \times \text{miR-320a}) + (0.094826 \times \text{miR-342-5p}) + (0.036391 \times \text{miR-3928-3p}) + (0.005184 \times \text{miR-4419b}) + \\ & (0.053273 \times \text{miR-4429}) + (0.417271 \times \text{miR-4447}) + (0.015554 \times \text{miR-4449}) + (-0.843683 \times \text{miR-4463}) + (-0.00283 \times \text{miR-4484}) + \\ & (0.029242 \times \text{miR-4515}) + (0.053746 \times \text{miR-4640-5p}) + (0.212297 \times \text{miR-4675}) + (0.076018 \times \text{miR-486-5p}) + (0.511782 \times \text{miR-557}) \\ & + (0.053403 \times \text{miR-6088}) + (-0.144789 \times \text{miR-642a-3p}) + (0.123975 \times \text{miR-6766-3p}) + (-0.319733 \times \text{miR-6799-5p}) + \\ & (-0.231024 \times \text{miR-6808-5p}) + (0.032697 \times \text{miR-6842-5p}) + (-0.505911 \times \text{miR-6858-5p}) + (0.001763 \times \text{miR-6877-5p}) + \\ & (0.007005 \times \text{miR-7108-3p}) + (-0.202289 \times \text{miR-718}) + (-0.479487 \times \text{miR-8089}) + (-0.117001 \times \text{miR-887-3p}) + \\ & (0.022773 \times \text{miR-939-5p}) + 17.907449 \end{aligned}$$

36-7 (Model TFlp \geq 36 months)

$$\begin{aligned} & (-0.0125433 \times \text{miR-1181}) + (0.1067349 \times \text{miR-1254}) + (0.0015947 \times \text{miR-1268b}) + (-0.3771727 \times \text{miR-187-5p}) + \\ & (0.0360527 \times \text{miR-191-5p}) + (-0.0984009 \times \text{miR-3141}) + (0.0233745 \times \text{miR-3195}) + (-0.5606837 \times \text{miR-3197}) + \\ & (0.2415774 \times \text{miR-320a}) + (0.1046963 \times \text{miR-342-5p}) + (0.0502296 \times \text{miR-3928-3p}) + (0.0009486 \times \text{miR-422a}) + \\ & (0.0050783 \times \text{miR-4419b}) + (0.05179 \times \text{miR-4429}) + (0.4470169 \times \text{miR-4447}) + (0.0210486 \times \text{miR-4449}) + \\ & (-0.9951068 \times \text{miR-4463}) + (-0.0335096 \times \text{miR-4484}) + (0.0152364 \times \text{miR-4515}) + (0.0870314 \times \text{miR-4640-5p}) + \end{aligned}$$

$$(0.2338915 \times \text{miR-4675}) + (0.0864322 \times \text{miR-486-5p}) + (0.5827542 \times \text{miR-557}) + (0.0782236 \times \text{miR-6088}) + (-0.1712249 \times \text{miR-642a-3p}) + (0.1380852 \times \text{miR-6766-3p}) + (-0.3991616 \times \text{miR-6799-5p}) + (-0.2738122 \times \text{miR-6808-5p}) + (0.0531576 \times \text{miR-6842-5p}) + (-0.5248665 \times \text{miR-6858-5p}) + (0.033589 \times \text{miR-7108-3p}) + (-0.2512049 \times \text{miR-718}) + (-0.5161003 \times \text{miR-8089}) + (-0.1219326 \times \text{miR-887-3p}) + (0.0626341 \times \text{miR-939-5p}) + 19.9189978$$

Supplementary Table 2.

AUC for all subgroups based on each model.

Model No.	Predict TFIp			
	> 1 month	≥ 6 months	≥ 12 months	≥ 36 months
Model TFIp > 1 month	0.944	0.663	0.603	0.618
Model TFIp ≥ 6 months	0.631	0.637	0.570	0.563
Model TFIp ≥ 12 months	0.757	0.698	0.705	0.659
Model TFIp ≥ 36 months	0.624	0.641	0.645	0.938

Note: Data are shown as AUC unless otherwise noted.